Drugs / PG-102
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00787137 | Dec 2008 → Apr 2010 | psoriatic arthritis | PanGenetics UK Limited | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07187856 | Jan → Sep 2026 expected | type 2 diabetes mellitus | ProGen. Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06712615 | Dec 2024 → Oct 2025 overdue | type 2 diabetes mellitus | ProGen. Co., Ltd. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06891287 Comparator | Dec 2025 → Dec 2026 expected | obesity disorder | RANI Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07187856 ↗ |
| Known as | MG12 | “* Participants will receive PG-102 by subcutaneous (SC) injection. * Other Names: MG12” NCT06712615 ↗ |
| Modality | Monoclonal antibody | “Anti-CD40 Monoclonal Antibody” NCT00787137 ↗ |
| Route | Intravenous | “A single intravenous infusion” NCT00787137 ↗ |
| Target | CD40 | “Anti-CD40 monoclonal antibody” NCT00787137 ↗ |